Table 1.
Baseline characteristics of the study population
| Characteristic of patients | Age | ||||
|---|---|---|---|---|---|
| Total N = 2830 | < 60 years old N = 850 | 60–75 years old N = 1489 | ≤75 years old N = 491 | p | |
| Age, yrs | 64.62 ± 10.54 | 51.63 ± 6.37 | 67.48 ± 4.23 | 78.42 ± 2.93 | < 0.001 |
| Gender, men, n (%) | 575(20.32) | 83(9.76) | 370(24.85) | 122(24.85) | < 0.001 |
| BMI, Kg/m2 | 24.20 ± 3.21 | 24.60 ± 2.95 | 24.12 ± 0.08 | 23.70 ± 0.17 | < 0.001 |
| Smoking, n (%) | 888(33.40) | 331(40.91) | 434(31.31) | 123(26.51) | < 0.001 |
| Drinking, n (%) | 647(24.80) | 237(30.15) | 320(23.49) | 90(19.52) | < 0.001 |
| Medical history | |||||
| Pre-hypertension, n (%) | 1546(54.86) | 357(42.20) | 870(58.55) | 319(65.64) | < 0.001 |
| Hyperlipidemia, n (%) | 474(16.83) | 169(19.98) | 257(17.32) | 48(9.86) | < 0.001 |
| Pre-diabetes mellitus, n (%) | 622(22.08) | 124(14.66) | 378(25.47) | 120(24.64) | < 0.001 |
| Laboratory values | |||||
| LVEF, % | 52.63 ± 23.07 | 51.26 ± 23.46 | 54.08 ± 22.01 | 50.49 ± 25.27 | < 0.001 |
| eGFR, ml/min/1.73m2 | 80.39 ± 40.97 | 93.49 ± 63.63 | 76.29 ± 23.84 | 70.11 ± 22.25 | < 0.001 |
| Total cholesterol, mmol/L | 4.09 ± 1.14 | 4.21 ± 1.29 | 4.04 ± 1.09 | 4.02 ± 0.97 | < 0.001 |
| LDL_C, mmol/L | 2.40 ± 0.94 | 2.52 ± 1.06 | 2.36 ± 0.90 | 2.31 ± 0.81 | < 0.001 |
| Blood glucose, mmol/L | 7.03 ± 3.22 | 6.8 ± 3.04 | 7.05 ± 3.39 | 7.37 ± 2.98 | 0.010 |
| Severity of CAD | |||||
| Number of stents, n | 1.87 ± 1.11 | 1.77 ± 1.07 | 1.88 ± 1.11 | 2.05 ± 1.14 | < 0.001 |
| Diagnose | |||||
| Unstable angina, n (%) | 1495(52.83) | 422(49.65) | 831(55.81) | 242(49.29) | < 0.001 |
| STEMI, n (%) | 392(13.85) | 139(16.35) | 179(12.02) | 74(15.07) | 0.010 |
| NSTEMI, n (%) | 180(6.36) | 40(4.71) | 99(6.65) | 41(8.35) | 0.030 |
| All death, n (%) | 270(9.54) | 35(4.12) | 143(9.60) | 92(18.74) | < 0.001 |
| CV death, n (%) | 150(5.30) | 23(2.71) | 76(5.10) | 51(10.39) | < 0.001 |
| Discharge medications | |||||
| Aspirin, n (%) | 2608(92.16) | 807(94.94) | 1374(92.28) | 427(86.97) | < 0.001 |
| Clopidogrel, n (%) | 2522(89.12) | 776(91.29) | 1332(89.46) | 414(84.32) | 0.006 |
| Dual-antiplatelet, n (%) | 2446(86.43) | 761(89.53) | 1288(86.50) | 397(80.86) | < 0.001 |
| Statin, n (%) | 2521(89.08) | 778(91.53) | 1307(87.78) | 436(88.80) | 0.023 |
| CCB, n (%) | 744(26.29) | 162(19.06) | 433(29.08) | 149(30.35) | < 0.001 |
| ACE inhibitors or ARBs, n (%) | 1603(56.64) | 436(51.29) | 880(59.10) | 287(58.45) | < 0.001 |
| Beta-receptor blockers, nw (%) | 1874(66.22) | 605(71.18) | 990(66.49) | 279(56.82) | < 0.001 |
Data are expressed as means± SD or counts and percentages, as appropriate. Abbreviations: BMI: body mass index, DM: diabetes mellitus, LVEF: left ventricular ejection fraction, eGFR: estimated glomerular filtration rate, LDL-C: low-density lipoprotein-cholesterol, STEMI: ST-segment elevated myocardial infarction, NSTEMI: non-ST-segment elevated myocardial infarction, SD: standard deviation. ACE, angiotensin-converting enzyme; ARBs, angiotensin-receptor blockers